What we do
& Why we do it
About Vetbiolix
Pets are playing an increasingly important role in human life. They are becoming full-fledged members of the family. This new status for dogs and cats has naturally led to significant specialization within the veterinary profession, requiring high-level diagnostic and therapeutic care.
At Vetbiolix, we are committed to developing leading, innovative therapeutic solutions for Osteoarthritis, Periodontitis, and Gut motility disorders. We have selected the most promising drug candidate programs currently under development in humans to develop them for dogs and cats.
In doing so, Vetbiolix fulfills its One Health mission: to bring on the market shared human-animal therapeutic innovation.
MISSION
- To bring 1st-in-class drug candidates on market for Companion Animals
Secret sauce
- Smart deals with Human Biotech: selecting appropriate 1st in-class drug candidates at clinical development stages in Human (Ph1 to Ph3) for Veterinary market
Know-how
- Veterinary Clinical strategy (POC, Pilot, Pivotal)
- CMC-Pharmaceutical Development
- Veterinary pharmacoeconomics
Osteoarthritis
CLINICAL TRIALS
Pilot clinical trial
on going (115 patients,
16 sites – Europe)
Osteoarthritis is a significant cause of pain, lameness and morbidity in dogs and many otherspecies, including humans. It is a multi-factorial, progressive, degenerative disease of synovial joints, affecting not only the articular cartilage but also other structures within the specific synovial joint. Degradation of articular cartilage, subchondral bone sclerosis, osteophytosis, varying degrees of synovitis, meniscal and ligament degeneration are all characteristics of the disease process.
At Vetbiolix, we are developing a first-in-class disease, potential disease-modifier, therapeutic agent for the treatment of Canine / Feline Osteoarthritis by (i) preventing cartilage degradation and (ii) reducing inflammation.
VBX-2000 is a first-in-class, oral small molecule, Adenosine-A3 Agonist for Osteoarthritis treatment
Periodontitis
Periodontal disease (PD) is the most widespread oral disease in dogs, with studies showing that 60–97% of dogs have some degree of PD (1–4). PD is defined as plaque-induced immune- mediated damage to the periodontium, which anchors the tooth in the maxillary and mandibular bones. If left untreated, PD becomes a slowly evolving chronic inflammatory disease that first affects the gingiva (gingivitis) and then propagates to deeper structures of the periodontium, leading to progressive tooth attachment loss due to damage to the periodontal ligaments and loss of alveolar bone (periodontitis).
At Vetbiolix, we are developing a first-in-class game-changer therapeutic agent for the treatment of Canine / Feline Periodontitis by (i) stopping alveolar bone resorption and (ii) promoting alveolar bone reformation.
VBX-1000 is a first-in-class, oral small molecule, Cathepsin-K inhibitor for Periodontitis treatment
CLINICAL TRIALS
Pilot clinical trial on going (60 patients, 10 sites – Europe)
Gut Motility Disorders
CLINICAL TRIALS
Proof of concept clinical trials in Dogs and Cats (30 patients – 5 sites – France)
Gastroparesis is very common in dog. It affects upper GI tract motility (stomach and duodenum), prevents proper movement of food from the stomach to the small intestine, and is associated with impaired gastric emptying. Gastroparesis results from abnormalities in smooth mucles function in the stomach and the duodenum.
Idiopathic Chronic constipation/megacolon (coprostase) is common in cat. Most cases occur in middle age (5-6 years). Pathogenesis is associated with abnormalities in colonic smooth muscles function.
At Vetbiolix we are developping a pure prokinetic agents to restore gastric motility of Pets
VBX-3000 is a first-in-class, oral small molecule, 5-HT4 agonist for gut motility disorders treatment